TUMOR ANTIGEN

摘要

Tumor antigen peptides (I) recognized by human leukocyte antigen (HLA)-A2 or HLA-A26 restricted cytotoxic T-cells (CTL) and/or capable of inducing CTL are new. Independent claims are also included for: (1) drug compositions containing peptides (I); (2) anticancer vaccines containing peptides (I); (3) inducing CTL using peptides (I); (4) polynucleotides encoding peptides (I), and their complementary chains; (5) expression vectors containing the polynucleotides of (4); (6) hosts transformed by the expression vectors of (5); (7) preparation of peptides (I) by culture of the transformed hosts of (6); (8) antibodies recognizing peptides (I); (9) screening compounds for improving the recognition of peptides (I) by CTL; (10) kits for performing the method of (9); (11) compounds identified by the method of (9); (12) drug compositions containing these compounds; (13) assay method for peptides (I); (14) detection and assay of polynucleotides including mRNA encoding peptides (I). ACTIVITY : Cytostatic. MECHANISM OF ACTION : Induction of CTL recognizing cancer cells. Data is given for in vitro recognition of peptides (I) by HLA-A2 restricted CTL measured by IFN-gamma production; up to 15-fold increase of IFNgamma is obtained using 20 Microg/ml (I) over control (a nonapeptide of HIV origin).